Sirinathsinghji D J
Brain Res. 1985 Jun 10;336(1):45-55. doi: 10.1016/0006-8993(85)90414-7.
A possible functional relationship between corticotropin-releasing factor (CRF) and opiate peptide neuronal systems (beta-endorphin, dynorphin1-17 and Met-enkephalin) and their interactions with gonadotropin releasing hormone (GnRH) in the mesencephalic central gray (MCG) for the regulation of lordosis behaviour was assessed in ovariectomized, oestrogen-treated and oestrogen-progesterone-treated female rats. Lordosis behaviour triggered by male mounting was inhibited in a dose-dependent fashion by CRF microinfused into the MCG in both oestrogen-treated and oestrogen-progesterone-treated female rats. This CRF-induced inhibition of lordosis could be overcome by a pre-infusion of naloxone or anti-beta-endorphin-globulin (anti-beta-end-G) directly into the MCG but not by anti-Met-enkephalin globulin (anti-enk-G) or anti-dynorphin1-17 globulin (anti-dynor-G). Supporting data indicate that the facilitation of lordosis behaviour induced by treatment with naloxone or anti-beta-end-G alone but not with anti-enk-G or anti-dynor-G may be due to enhanced GnRH release. This results from the action of these substances in overcoming the inhibition of GnRH secretion mediated specifically by beta-endorphin but not by Met-enkephalin or dynorphin1-17 in the MCG. These studies together with previous data showing that GnRH can overcome the abolition of lordosis by beta-endorphin in the MCG, indicate a close relationship between beta-endorphin (but not Met-enkephalin or dynorphin) and GnRH systems in the MCG in the control of lordosis behaviour. Thus, the inhibition of lordosis by CRF and the complete reversal of this blockade by naloxone or anti-beta-end-G may suggest that CRF could enhance the release of beta-endorphin from fibres in the MCG; beta-endorphin then inhibits lordosis by inhibiting the release of GnRH. However, a direct inhibitory effect of CRF on GnRH release is also likely since anti-CRF-gamma-globulin (anti-CRF-G) infused into the MCG produced a long-lasting facilitation of lordosis which can be blocked by an antagonist analogue of GnRH; in addition, previous studies have shown that GnRH infused into the MCG completely overcame the CRF-induced abolition of lordosis and potentiated lordosis to high levels. These results suggest that there may be functional neuroanatomical relationships between CRF, beta-endorphin and GnRH neuronal systems in the MCG in the control of female sexual behaviour. Neither Met-enkephalin nor dynorphin1-17 appear to participate in such mechanisms.
在去卵巢、接受雌激素处理以及接受雌激素 - 孕酮处理的雌性大鼠中,评估了促肾上腺皮质激素释放因子(CRF)与阿片肽神经元系统(β - 内啡肽、强啡肽1 - 17和甲硫氨酸脑啡肽)之间可能的功能关系,以及它们在中脑中央灰质(MCG)中与促性腺激素释放激素(GnRH)的相互作用对脊柱前凸行为的调节作用。在雌激素处理和雌激素 - 孕酮处理的雌性大鼠中,向MCG微量注射CRF会以剂量依赖的方式抑制雄性爬跨引发的脊柱前凸行为。预先向MCG直接注射纳洛酮或抗β - 内啡肽球蛋白(抗β - end - G)可克服CRF诱导的这种脊柱前凸抑制,而抗甲硫氨酸脑啡肽球蛋白(抗enk - G)或抗强啡肽1 - 17球蛋白(抗dynor - G)则不能。支持数据表明,单独用纳洛酮或抗β - end - G处理而非抗enk - G或抗dynor - G处理所诱导的脊柱前凸行为促进作用,可能是由于GnRH释放增强所致。这是因为这些物质能够克服MCG中由β - 内啡肽而非甲硫氨酸脑啡肽或强啡肽1 - 17介导的GnRH分泌抑制作用。这些研究以及先前的数据表明,GnRH能够克服MCG中β - 内啡肽对脊柱前凸的消除作用,这表明在控制脊柱前凸行为方面,MCG中的β - 内啡肽(而非甲硫氨酸脑啡肽或强啡肽)与GnRH系统之间存在密切关系。因此,CRF对脊柱前凸的抑制以及纳洛酮或抗β - end - G对这种阻断的完全逆转可能表明,CRF可增强MCG中纤维释放β - 内啡肽;然后β - 内啡肽通过抑制GnRH释放来抑制脊柱前凸。然而,CRF对GnRH释放也可能有直接抑制作用,因为向MCG注射抗CRF - γ球蛋白(抗CRF - G)会产生对脊柱前凸的持久促进作用,而这可被GnRH的拮抗剂类似物阻断;此外,先前的研究表明,向MCG注射GnRH可完全克服CRF诱导的脊柱前凸消除并将脊柱前凸增强到高水平。这些结果表明,在控制雌性性行为方面,MCG中的CRF、β - 内啡肽和GnRH神经元系统之间可能存在功能性神经解剖学关系。甲硫氨酸脑啡肽和强啡肽1 - 17似乎均不参与此类机制。